Who invested in Acrivon Therapeutics

One round we have observed, with the 5 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$130Mraised across 1 round since 2024, from 1 source

Latest round: Round, $130MApr 2024
Investors: 5

See who backed them

The rounds

Apr 2024
Round$130M
Source recorded

Founders and team

From Acrivon Therapeutics's own website and the SEC filings it signed: 2 founders, 10 on the team.

Peter Blume-JensenCEO, President, Founder ChairpersonNamed on its 2021 Form D

Kristina MassonCo-Founder, EVP, Business Operations, Site Head, DirectorNamed on its 2021 Form D

Adam D. LevyChief Financial Officer
Mary-Alice MillerChief Legal Officer
Michaela LevinChief Business Officer
Eric DevroeChief Operating Officer
Erick GamelinChief Development Officer
Ivana Magovčević-LiebischDirector
Michael TomsicekDirector
Santhosh PalaniDirector
Derek DiRoccoDirector
Sharon ShachamDirector

On the board, as filediMarcin Czernik

Everyone who backed them

New Enterprise AssociatesVC firm1round

RA Capital ManagementPrivate equity1round

Wellington ManagementVC firm1round

Perceptive AdvisorsAsset manager1round

Sands Capital VenturesPrivate equity1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Acrivon Therapeutics

Who invested in Acrivon Therapeutics?

Acrivon Therapeutics's investors include New Enterprise Associates, RA Capital Management, Wellington Management, Perceptive Advisors and Sands Capital Ventures.

How much has Acrivon Therapeutics raised?

Acrivon Therapeutics has raised $130M across 1 round since 2024.

When did Acrivon Therapeutics last raise?

Acrivon Therapeutics's most recent round was an Undisclosed round of $130M in Apr 2024.

What was Acrivon Therapeutics's biggest round?

Its most recent round, $130M in Apr 2024, is also its largest on record.

Who backed Acrivon Therapeutics first?

Acrivon Therapeutics's first round on record, in Apr 2024, was backed by New Enterprise Associates, RA Capital Management and Wellington Management and 2 others.